Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

86.20 -1.25 (-1.43%)

Streaming Delayed Price Updated: 1:12 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

72 73 Next >

First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories ↗

May 01, 2023

Benzinga

Via Benzinga

European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals ↗

May 01, 2023

The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public...

Via Benzinga

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks? ↗

April 28, 2023

Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.

Via Investor's Business Daily

How To Attend BioNTech Q1 2023 Earnings Conference Call ↗

April 27, 2023

Via Benzinga

Buy This Pharma Powerhouse With A 4% Yield ↗

April 21, 2023

Imagine a company whose stock hit an all-time in December 2021 after soaring 50% that year. And that company’s sales doubled in the two years leading up to 2022. And its operating profits quadrupled.

Via Talk Markets

P/E Ratio Insights for BioNTech ↗

April 20, 2023

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

April 17, 2023

Via Benzinga

BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023

April 24, 2023

From BioNTech SE

Via GlobeNewswire

Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't? ↗

April 20, 2023

The company is facing a litigation headwind and continued competition.

Via Investor's Business Daily

7 Low-PE Ratio Blue-Chip Stocks Offering Both Quality and Value ↗

April 19, 2023

Make your dollars go as far as possible (and relatively safely) with these low-PE ratio blue-chip stocks to buy.

Via InvestorPlace

FDA Gives Green Signal To Second Omicron-Adapted Booster Shots For People At High Risk From Covid ↗

April 18, 2023

Via Benzinga

What 12 Analyst Ratings Have To Say About BioNTech ↗

April 10, 2023

Via Benzinga

A Look Into BioNTech Inc's Price Over Earnings ↗

April 03, 2023

Via Benzinga

Bear of the Day: BioNTech ↗

March 28, 2023

BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines.

Via Talk Markets

These Analysts Revise Price Targets On BioNTech After Q4 Results ↗

March 28, 2023

BioNTech SE (NASDAQ: BNTX) reported a decline in sales for its fourth quarter.

Via Benzinga

US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma ↗

April 12, 2023

Via Benzinga

Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments ↗

April 11, 2023

The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a...

Via Benzinga

Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal ↗

April 08, 2023

Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...

Via Talk Markets

Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗

April 04, 2023

Via Benzinga

Why Shares of BioNTech Slumped Monday ↗

March 27, 2023

The company released fourth-quarter earnings.

Via The Motley Fool

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech

April 04, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

April 03, 2023

From BioNTech SE

Via GlobeNewswire

Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review ↗

March 31, 2023

The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica.

Via Investor's Business Daily

NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 28, 2023

B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8%...

Via Benzinga

BioNTech Announces New ADS Repurchase Program

March 28, 2023

From BioNTech SE

Via GlobeNewswire

Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories ↗

March 27, 2023

Benzinga

Via Benzinga

BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday ↗

March 27, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

BioNTech Is Ripe For A Rebound In 2023

March 27, 2023

BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma.

Via MarketBeat

Topics Intellectual Property

BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion ↗

March 27, 2023

For the year, BioNTech said it expects about $5.4 billion in sales of its Covid shot.

Via Investor's Business Daily

Why BioNTech Shares Are Trading Lower Today ↗

March 27, 2023

BioNTech SE (NASDAQ: BNTX) shares are falling in the premarket session today after the company reported Q4 earnings and expected lower annual revenue from the Covid-19 vaccine.

Via Benzinga

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.